{"brief_title": "Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin\u00b4s Follicular Lymphoma", "brief_summary": "The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Follicular Lymphoma (FL).", "condition": ["Lymphoma, Follicular"], "intervention_type": ["Drug"], "intervention_name": ["HuMax-CD20"], "criteria": "Inclusion Criteria: - Relapsed or refractory follicular lymphoma grade I-II - Tumor verified to be CD20 positive - CT scan showing demarcated lesions Exclusion Criteria: - Previous treatment with rituximab resulting in less than partial response - Previous radioimmunotherapy - Previous stem cell transplantation - Received the following treatments within 4 weeks prior to entering this study: 1. Anti-cancer therapy 2. Glucocorticosteroids unless less than 10 mg prednisolone/day 3. Radiotherapy - Received Mitomycin C or Nitrosoureas within 6 weeks prior to entering this trial - HIV positivity - Hepatitis B or hepatitis C - Uncontrolled or chronic bacterial, fungal or viral infection - Other cancer diseases, except certain skin cancers, cervix cancer and breast cancer - Certain serious medical conditions, including kidney or liver disease, some psychiatric illnesses, and stomach, lung, heart, hormonal, nerve or blood diseases - WHO performance status of 3 or 4 - If you are participating in another trial with a different new drug 4 weeks before you enter this trial - Current participation in any other clinical study - Pregnant or breast-feeding women - Women of childbearing age who are unable or unwilling to use an IUD or hormonal birth control during the whole trial", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Non Hodgkin\u00b4s Lymphoma", "mesh_term": ["Lymphoma", "Lymphoma, Follicular", "Antibodies, Monoclonal"], "id": "NCT00092274"}